We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Complete Response Letters, NDA Filings Proposed for FDA Transparency
Complete Response Letters, NDA Filings Proposed for FDA Transparency
May 21, 2010
The FDA should disclose whenever an NDA, ANDA or BLA is submitted or withdrawn by a drugmaker, as well as detailed information about the company and the proposed product, an agency task force has recommended.